The new CLL MASTR Plus kit with nine genes that are frequently mutated in CLL will be able to detect single nucleotide variants and copy number alterations.
According to the company, the identification of mutations in TP53, BIRC3, NOTCH1 and SF3B1 enables a more refined prognostic stratification.
While, the detection of TP53 mutations has therapeutic value as it guides treatment with alemtuzumab and/or steroids, which may be followed by allogeneic stem cell transplantation.
The new test will guide treatment options including personalized medicine to treat patients with CLL.
Multiplicom CTO Jurgen Del Favero said: "The composition of the gene panel was established in collaboration with key opinion leaders in the diagnosis and treatment of CLL.
"The CLL MASTR Plus kit is based on Multiplicom’s MASTR technology, delivering a simple, fast and affordable genetic test to labs.
"The MASTR kits are compatible with the leading NGS platforms, and have been subjected to state of the art quality control measures ensuring reproducible results."
